Cancer Letters
Volume 208, Issue 2 , Pages 179-186, 28 May 2004

In vivo reversal of doxorubicin resistance by (−)-epigallocatechin gallate in a solid human carcinoma xenograft

State Key Laboratory of Bioreactor Engineering, New World Institute of Biotechnology, East China University of Science and Technology, Shanghai 200237, People's Republic of China

Received 22 September 2003; received in revised form 27 January 2004; accepted 28 January 2004.

Abstract 

A human carcinoma xenograft model was established with resistant KB-A-1 cell line in order to investigate whether (−)-epigallocatechin gallte (EGCG) can reverse doxorubicin (DOX) resistance in vivo. EGCG could sensitize the tumors to DOX as indicated by a considerable reduction of tumor weights. The combination of DOX with EGCG increased the DOX concentration by 51% in the tumors, and increased DOX-induced apoptosis in the tumors compared with DOX alone. In addition, the combination schedules appeared to be well tolerated. We conclude that EGCG could chemosensitize resistant tumor cells to DOX in vivo through an increase in the accumulation of DOX in the tumors.

Keywords:  (−)-Epigallocatechin gallte (EGCG), Doxorubicin, Resistance, Tumor, Nude mice

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0304-3835(04)00137-5

doi:10.1016/j.canlet.2004.01.033

Refers to erratum:

  • Erratum to ‘In vivo reversal of doxorubicin resistance by (−)-epigallocatechin gallate in a solid human carcinoma xenograft’ [Cancer Letters 208 (2004) 179–186]☆

    Qiang Zhang, Dongzhi Wei, Jianwen Liu
    Cancer Letters 8 November 2005 (Vol. 229, Issue 1, Page 149)

Cancer Letters
Volume 208, Issue 2 , Pages 179-186, 28 May 2004

Article Tools

* Image Usage & Resolution